Equillium director receives 70,000 stock options

Equillium, Inc. director Charles Douglas McDermott received a grant of stock options covering 70,000 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Equillium, Inc. director Charles Douglas McDermott received a grant of stock options covering 70,000 shares of common stock. The options have an exercise price of $2.84 per share and expire on May 27, 2036.

The award vests in twelve equal monthly installments starting on May 28, 2026, and will in any case be fully vested on the date of Equillium's next annual meeting of stockholders following the grant date. Following this grant, McDermott holds 70,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 70,000 shares

Grant/Award 1 txn

Insider McDermott Charles Douglas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	70,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 70,000 contracts (Direct)

Footnotes (1)

F1. The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Key Figures

Option grant size: 70,000 options Exercise price: $2.84 per share Expiration date: May 27, 2036 +2 more

5 metrics

Option grant size 70,000 options Director stock option covering common shares

Exercise price $2.84 per share Strike price for the stock option

Expiration date May 27, 2036 Option expiration

Vesting schedule 12 equal monthly installments Beginning May 28, 2026

Holdings after grant 70,000 derivative securities Total options held following transaction

Key Terms

Director Stock Option, grant/award acquisition, exercise price, vests in twelve equal monthly installments, +1 more

5 terms

Director Stock Option financial

"security_title: "Director Stock Option (right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "2.8400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in twelve equal monthly installments financial

"The option vests in twelve equal monthly installments"

annual meeting of stockholders financial

"fully vested on the date of the Issuer's annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Equillium (EQ) director Charles Douglas McDermott report on this Form 4?

Director Charles Douglas McDermott reported receiving a stock option grant for 70,000 shares of Equillium common stock. The options are a compensation-related award, not an open-market purchase or sale of existing shares, and are held directly in his name.

What are the key terms of Charles McDermott’s Equillium (EQ) stock option grant?

The grant covers 70,000 shares of Equillium common stock at an exercise price of $2.84 per share. The options expire on May 27, 2036, giving a long exercise window as part of his director compensation package.

How do Charles McDermott’s Equillium (EQ) options vest over time?

The options vest in twelve equal monthly installments beginning on May 28, 2026. However, they will be fully vested no later than the date of Equillium’s annual meeting of stockholders following the grant date, accelerating full vesting by that meeting.

Is Charles McDermott’s Form 4 for Equillium (EQ) a stock purchase or sale?

The Form 4 reports a grant of stock options, classified as an acquisition under code A. It is a compensation award rather than an open-market buy or sell, and no sale of Equillium common shares is disclosed in this filing.

How many Equillium (EQ) derivative securities does Charles McDermott hold after this transaction?

After the reported transaction, Charles McDermott holds 70,000 derivative securities related to Equillium common stock. These represent the options granted in this award and reflect his position immediately following the grant’s reporting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/29/2026 - 06:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McDermott Charles Douglas

(Last)

(First)

(Middle)

2223 AVENIDA DE LA PLAYA, SUITE 105

(Street)

LA JOLLA

CALIFORNIA

92037

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Equillium, Inc. [ EQ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$2.84	05/28/2026		A		70,000		⁽¹⁾	05/27/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

	/s/ Daniel M. Bradbury, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR